Benzazine derivatives as phosphodiesterase 4 inhibitors
    1.
    发明授权
    Benzazine derivatives as phosphodiesterase 4 inhibitors 失效
    苯并嗪衍生物作为磷酸二酯酶4抑制剂

    公开(公告)号:US06358973B1

    公开(公告)日:2002-03-19

    申请号:US09806496

    申请日:2001-04-13

    IPC分类号: C07D4006

    CPC分类号: C07D401/06

    摘要: Compounds of formula I: wherein A is a heterocycle containing a nitrogen atom and optionally saturated or unsaturated and optionally further substituted by an oxo group (═O); R is: hydrogen, cyano, (C1-4)alkoxycarbonyl, carbamoyl; optionally substituted (C4-7)-cycloalkyl, aryl or heterocycle; (C1-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl optionally branched and/or substituted by (C4-7) cycloalkyl, aryl or heterocycle; aryloxy, heterocyclyloxy, aryl(C1-4)alkoxy, heterocyclyl(C1-4)alkoxy, amino substituted by one or two (C1-4)alkyl group(s), aryl-amino, heterocyclyl-amino, aryl(C1-4)alkyl-amino, or heterocyclyl(C1-4)alkylamino; Y is methylene or ethylene; W is an optionally substituted aryl or heterocycle; R1 is hydrogen, (C4-7)cycloalkyl or a (C2-8)alkyl, (C2-8)alkenyl or (C2-8)alkynyl group optionally substituted by hydroxy, oxo, (C4-7)cycloalkyl, aryl or heterocycle, and optionally interrupted by one or more heteroatom(s) or heterogroup(s); R2 is a (C1-6)alkyl or polyfluoro(C1-6)alkyl group; the N→O derivatives of the compounds of formula I and the pharmaceutically acceptable salts thereof. The compounds of formula (I) are PDE 4 inhibitors and may be used in compositions and methods involving PDE 4 inhibition.

    摘要翻译: 式I化合物:其中A是含有氮原子,任选饱和或不饱和并任选进一步被氧代基(= O)取代的杂环; R为:氢,氰基,(C 1-4)烷氧基羰基,氨基甲酰基; 任选取代的(C 4-7) - 环烷基,芳基或杂环; (C 1-8)烷基,(C 2-8)烯基或任选被(C 4-7)环烷基,芳基或杂环支链和/或取代的(C 2-8)炔基; 芳氧基,杂环氧基,芳基(C 1-4)烷氧基,杂环基(C 1-4)烷氧基,被一个或两个(C 1-4)烷基取代的氨基,芳基 - 氨基,杂环基 - 氨基,芳基 )烷基 - 氨基或杂环基(C 1-4)烷基氨基; Y是亚甲基或亚乙基; W是任选取代的芳基或杂环; R1是氢,(C4-7)环烷基或(C2-8)烷基,(C2-8)烯基或(C2-8)炔基,任选被羟基,氧代,(C 4-7)环烷基,芳基或杂环 并且任选被一个或多个杂原子或杂团中断; R2是(C1-6)烷基或多氟(C1-6)烷基; 式I化合物的N-> O衍生物及其药学上可接受的盐。 式(I)化合物是PDE 4抑制剂,可用于涉及PDE4抑制的组合物和方法。

    Phthalazine derivatives phosphodiesterase 4 inhibitors
    2.
    发明授权
    Phthalazine derivatives phosphodiesterase 4 inhibitors 失效
    酞嗪衍生物磷酸二酯酶4抑制剂

    公开(公告)号:US06329370B1

    公开(公告)日:2001-12-11

    申请号:US09743813

    申请日:2001-01-22

    IPC分类号: A61K315377

    摘要: The present invention provides a compound selected from the group including: 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-phenyl-phthalazine; 4-(3,5-dichloro-pyridin-4-ylmethyl)-7-methoxy-1H-phthalazin-2-carboxylic acid methyl ester; benzyl-{3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-ynyl}-methyl-amine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-5-(5-morpholin-4-yl-pent-1-ynyl)-phthalazine dihydrochloride; 3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-yn-1-ol; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-morpholin-4-yl-phthalazine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-(1,2,4)triazol-1-yl-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition which includes a therapeutically effective amount of the above compound in admixture with a suitable carrier.

    摘要翻译: 本发明提供了选自以下的化合物:1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基-4-苯基 - 酞嗪; 4-(3,5-二氯 - 吡啶-4-基甲基)-7-甲氧基-1H-酞嗪-2-甲酸甲酯; 苄基 - {3- {1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基 - 二氮杂萘-5-基} - 丙-2-炔基} - 甲基 - 胺; 1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基-5-(5-吗啉-4-基 - 戊-1-炔基) - 酞嗪二盐酸盐; 3- {1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基 - 二氮杂萘-5-基} - 丙-2-炔-1-醇; 1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基-4-吗啉-4-基 - 酞嗪; 1-(3,5-二氯 - 吡啶-4-基甲基)-6-甲氧基-4-(1,2,4)三唑-1-基 - 酞嗪; 其N-> O衍生物; 及其药学上可接受的盐。 本发明还提供一种药物组合物,其包含治疗有效量的上述化合物与合适的载体的混合物。

    Phthalazine derivatives as phosphodiesterase 4 inhibitors
    3.
    发明授权
    Phthalazine derivatives as phosphodiesterase 4 inhibitors 失效
    酞嗪衍生物作为磷酸二酯酶4抑制剂

    公开(公告)号:US06340684B1

    公开(公告)日:2002-01-22

    申请号:US09764983

    申请日:2001-01-22

    IPC分类号: A61K31502

    摘要: The present invention provides a compound selected from the group including: N-3-acetyl-1-(3,5-dichloropyridin-4-ylmethyl)-5-cyclopentyloxy-6-methoxy-4H-phthalazine; 6,7-dimethoxy-1-pyridin-4-ylmethyl-4-thiazol-2-yl-phthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)ethanone; 2-methanesulphonyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 2-formyl-6,7-dimethoxy-4-pyridin-4-ylmethyl-1,2-dihydrophthalazine; 1-(6,7-dimethoxy-4-pyridin-4-ylmethyl-1H-phthalazin-2-yl)-1-imidazol-1-ylmethanone; 1-(3,5-dichloro-pyridin-4-ylmethyl)-3-methansulphonyl-6-difluoromethoxy-5-(tetrahydro-furan-2-yloxy)-4H-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition, which contains a therapeutically effective amount of the above compound in admixture with a pharmaceutically acceptable carrier.

    摘要翻译: 本发明提供了选自以下的化合物:N-3-乙酰基-1-(3,5-二氯吡啶-4-基甲基)-5-环戊基氧基-6-甲氧基-4H-酞嗪; 6,7-二甲氧基-1-吡啶-4-基甲基-4-噻唑-2-基 - 酞嗪; 1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-酞嗪-2-基)乙酮; 2-甲磺酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢酞嗪; 2-甲酰基-6,7-二甲氧基-4-吡啶-4-基甲基-1,2-二氢酞嗪; 1-(6,7-二甲氧基-4-吡啶-4-基甲基-1H-酞嗪-2-基)-1-咪唑-1-基甲酮; 1-(3,5-二氯 - 吡啶-4-基甲基)-3-甲磺酰基-6-二氟甲氧基-5-(四氢 - 呋喃-2-基氧基)-4H-酞嗪; 其N-> O衍生物; 及其药学上可接受的盐。 本发明还提供一种药物组合物,其含有治疗有效量的上述化合物与药学上可接受的载体的混合物。

    Phthalazine derivatives phosphodiesterase 4 inhibitors

    公开(公告)号:US06492360B1

    公开(公告)日:2002-12-10

    申请号:US09976436

    申请日:2001-10-15

    IPC分类号: A61K31502

    摘要: Compounds of formula (I), wherein is a single or double bond; Z is NH, methylene, a (C2-C6)alkylene chain optionally branched and/or unsaturated and/or interrupted by a (C5-C7)cycloalkyl residue; A is phenyl or heterocycle optionally substituted or a COR4 group wherein R4 is hydroxy, (C1-C6)-alkoxy, amino optionally substituted; R is a (C1-C6)alkyl or polyfluoro(C1-C6)alkyl group; R1 is absent when is a double bond or, when is a single bond, is (a) hydrogen; (b) (C1-C6)alkyl optionally substituted; (c) —COR6 wherein R6 is hydrogen, aryl, aryl-(C1-C6)alkyl, amino optionally alkylated or monohydroxylated, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, formula (1), or (C1-C4)alkyl optionally substituted by heterocycle; (d) (C1-C4)-alkylsulfonyl; R2 represents two hydrogen atoms or a group —O when is a single bond, or, when is a double bond, R2 is hydrogen, cyano, (C1-C4)alkoxycarbonyl, amido, optionally substituted aryl or heterocycle, (C1-C8)alkyl, (C2-C8)alkenyl or (C2-C8)alkynyl optionally branched and/or substituted; aryloxy, heterocyclyloxy, aryl-(C1-C4)alkoxy, heterocyclyloxy-(C1-C4)alkoxy, amino substituted by one or two (C1-C4)-alkyl group(s), arylamino, heterocyclylamino, aryl-(C1-C4)alkylamino, heterocyclyl-(C1-C4)-alkylamino; R3 is hydrogen, or a (C1-C8)alkyl, (C2-C8)alkenyl or (C2-C8)alkynyl group optionally substituted, and optionally interrupted; the N→O derivatives of the compounds of formula (I) and the pharmaceutically acceptable salts thereof are PDE 4 inhibitors.